Skip to main content

Table 5 Results of the paired-samples t-tests (before and after treatment) according to genotype

From: Positive association of the hepatic lipase gene polymorphism c.514C > T with estrogen replacement therapy response

Genotype Variable
(mg/dL)
N Mean Standard Deviation t-test p
CC TotalChol 15 216.27 47.36 0.15 0.89
  TotalChol 2 15 214.60 39.09   
CT TotalChol 29 205.41 44.03 0.08 0.94
  TotalChol 2 29 204.66 39.76   
TT TotalChol 14 214.07 48.65 0.03 0.98
  TotalChol 2 14 213.71 55.03   
CC HDL-C 15 57.87 12.56 1.31 0.21
  HDL-C 2 15 54.87 15.47   
CT HDL-C 29 57.17 12.18 0.21 0.84
  HDL-C 2 29 56.76 13.38   
TT HDL-C 14 63.79 16.44 0.36 0.72
  HDL-C 2 14 62.93 15.16   
CC LDL-C 15 134.40 42.83 -0.09 0.93
  LDL-C2 15 135.40 34.27   
CT LDL-C 29 118.21 31.19 -0.14 0.89
  LDL-C2 29 19.62 38.01   
TT LDL-C 14 108.50 45.96 -1.26 0.23
  LDL-C2 14 127.14 42.28   
CC TG 15 132.60 45.50 1.07 0.30
  TG2 15 121.13 44.02   
CT TG 29 136.41 70.19 1.20 0.24
  TG2 29 121.83 73.78   
TT TG 14 147.36 76.01 1.71 0.11
  TG2 14 123.57 74.68   
  1. TotalChol: total pre-treatment cholesterol; HDL-C: pre-treatment high-density lipoprotein cholesterol; LDL-C: pre-treatment low-density lipoprotein cholesterol; TG: pre-treatment triglycerides; TotalChol2: total post-treatment cholesterol; HDL-C2: post-treatment high-density lipoprotein cholesterol; LDL-C2: post-treatment low-density lipoprotein cholesterol; TG2: post-treatment triglycerides; CC: homozygous major-allele genotype; CT: heterozygous genotype; TT: homozygous minor-allele genotype.